How much revenue does Shanghai Henlius Biotech make?

Shanghai Henlius Biotech reported 6.67 billion CNY in revenue for fiscal year 2025, up 16.5% from 5.72 billion CNY in fiscal year 2024.

Where does Shanghai Henlius Biotech make most of its revenue?

Chinese Mainland: 87% of revenue by region in fiscal year 2025, followed by North America (7%).

What companies are similar to Shanghai Henlius Biotech?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Innovent BIO (1801.HK), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), Akeso, Inc. (9926.HK), Keymed Biosciences Inc. (2162.HK).

Shanghai Henlius Biotech, Inc. (2696.HK) Stock

About Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rhe...

At a glance

Shanghai Henlius Biotech reported revenue of 6.67 billion CNY for fiscal year 2025, up 16.5% from fiscal year 2024, and net income of 827.04 million CNY. Chinese Mainland was its largest region in fiscal year 2025, with 87% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.